Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUPITA study of standard versus dose-escalation fruquintinib in metastatic colorectal cancer
jRCTs041260036Phase 3Recruiting
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fruquintinib in colorectal cancer (CRC) (2 arms). Primary endpoints: Disease control rate and Overall survival. Started May 2026; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041260036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260036.